What information should a sponsor of a randomized trial receive during its conduct?

Clinical Trials

Volumn 8, Issue 6, 2011, Pages 716-719

  Anand, Sonia S ^a,b   Wittes, Janet ^c   Yusuf, Salim ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c University of Iowa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; BOARD OF TRUSTEES; CANADA; FUNDING; HUMAN; HUMAN RELATION; INDEPENDENCE; INFORMATION; NAMED GROUPS BY OCCUPATION; PEER REVIEW; PRIORITY JOURNAL; PROBABILITY; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSIBILITY; SPONSOR;

ADVISORY COMMITTEES; CANADA; CLINICAL TRIALS DATA MONITORING COMMITTEES; DISCLOSURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY MANAGEMENT;

EID: 83455162665     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511424421     Document Type: Article

References (6)

1. Ellenberg S, Fleming T, DeMets D Data Monitoring Committees in Clinical Trials: A Practical Perspective. West Sussex: John Wiley & Sons ; 2002 :
2. Friedman L, Furberg C, DeMets D Monitoring Response Variables in Fundamentals of Clinical Trials. New York: Springer- Verlag ; 1998 :
3. Wittes J, Barrett-Connor E, Braunwald E, et al. Monitoring the WHI trials: The data and safety monitoring board experience. Clin Trials. 2007 ; 4: 218-35
4. Tardif JC, McMurray JJ, Klug E, et al. Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: A randomised, double-blind, placebo-controlled trial. Lancet. 2008 ; 371 (9626). 1761-68 (Pubitemid 351697951)
5. Hemmings R, Day S. Regulatory perspectives on data safety monitoring boards: Protecting the integrity of data. Drug Saf. 2004 ; 27 (1). 1-6 (Pubitemid 38186934)
6. Anand S, Yusuf S, Xie C, et al. Warfarin antiplatelet vascular evaluation trial investigators. N Engl J Med. 2007 ; 357 (3). 217-27